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Abstract
Donor–acceptor cyclopropanes are convenient precursors to reactive and versatile 1,3-dipoles, and 
have found application in the synthesis of a variety of carbo- and heterocyclic scaffolds. This 
perspective review details our laboratory’s use of donor–acceptor cyclopropanes as intermediates 
toward the total synthesis of various natural products. We also discuss our work in the 
development of novel cycloadditions and rearrangements of donor–acceptor cyclopropanes and 
aziridines, as well as an example of an aryne insertion proceeding via fragmentation of a transient 
donor–acceptor cyclobutane.
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1. Introduction
Donor–acceptor cyclopropanes (1, Scheme 1), or those possessing one or more electron-
donating groups and electron-withdrawing groups on adjacent carbons, are useful building 
blocks in organic synthesis.[1] Due to the presence of these vicinal charge-stabilizing groups 
and the strain inherent to the cyclopropane core, ring opening can occur under mild 
conditions. Typically, treatment with a Lewis acid at room temperature is sufficient to induce 
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carbon–carbon bond cleavage, leading to an all-carbon 1,3-dipole (2). These dipoles are 
generally quite versatile, having been shown to undergo nucleophilic trapping, electrophilic 
trapping, or dipolar cycloadditions to form a wide array of products (3–6, Scheme 1).
The acceptor groups are often carbonyl derivatives (with esters, ketones, and nitriles most 
common), although other electron-withdrawing groups, including sulfonyl, sufinyl, and 
phosphoryl, are occasionally used. Traditional donor groups are alkoxy, silyloxy, and amino 
substituents. Over the past decade, however, the use of aryl donor groups has become 
widespread, pioneered by the work of Kerr[2] and Johnson.[3] Aryl-substituted 
cyclopropanes are readily available in one or two steps from styrenes or benzaldehydes 
using straightforward methods.[1a] These compounds are typically more stable than 
cyclopropanes with heteroatom-based donors, and in some circumstances are capable of 
undergoing stereospecific reactions.[4]
Our laboratory’s interest in donor–acceptor cyclopropanes was sparked during the PI’s use 
of cyclopropane fragmentations (classified as electrophilic trapping in Scheme 1) as a 
method of ring expansion in the synthesis of K252a and the welwitindolinone C 
isothiocyanate core during his graduate studies in the Wood group. This perspective review 
describes this work in more detail below, and proceeds to examine our continued use of 
donor–acceptor cyclopropane fragmentations and cycloadditions toward the total synthesis 
of natural products. Our past and current efforts in this vein have also inspired the 
development of several new methods utilizing cyclopropane and aziridine rearrangements 
and cycloadditions, which are also discussed. Finally, we present a serendipitously 
discovered aryne C–C insertion reaction which is believed to proceed via fragmentation of a 
transient donor–acceptor cyclobutane intermediate.
2. Use of Donor–Acceptor Cyclopropanes as Intermediates in Natural 
Products Synthesis
2.1 Total Synthesis of K252a
Our interest in the use of donor–acceptor cyclopropanes as intermediates in natural products 
total synthesis began with the synthesis of K252a (7, Scheme 2) by one of us in the Wood 
laboratory at Yale University.[5] Isolated in 1985 by Sezaki and co-workers from a culture of 
the soil bacterium Actinomadura sp. SF-2370,[6] (+)-K252a was found to possess nanomolar 
inhibitory activity against protein kinase C.[7] Subsequent studies showed that structurally 
related compounds possess similar activity, and suggested these indolocarbazole alkaloids 
may have potential in the treatment of cancers[8] and neurodegenerative diseases.[9]
Stoltz, Wood, and co-workers envisioned accessing K252a (7) by late stage glycosylation of 
an indolocarbazole precursor 8, itself constructed by coupling of diazolactam 11[10] and 
2,2’-biindole[11] (10, Scheme 2). Indoles had been functionalized at the C3-position by 
treatment with carbenes or metal carbenoids, with the reactions proceeding through 
cyclopropanation of the indole C2–C3 bond and subsequent by fragmentation.[12]
Extensive experimentation revealed that treatment of a mixture of 11 and 10 with 1 mol % 
rhodium(II) acetate in pinacolone at 120 °C furnished the desired indolocarbazole 8 in 62% 
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yield.[13] Although no intermediates could be observed by TLC or NMR, the reaction is 
presumed to proceed via the transient donor–acceptor cyclopropane 12 produced by 
cyclopropanation of the rhodium carbenoid onto an indole C2–C3 bond (Scheme 3). This 
cyclopropane is expected to rapidly fragment to form the more stable enol biindole 13, 
which can undergo a 6π electrocyclic ring closure, followed by dehydrative aromatization to 
form 8. Small amounts of hemiaminal 15 were also obtained in the reaction, and subjection 
of this material to xylenes at reflux or CSA resulted in quantitative conversion to 8. It was 
postulated that this byproduct was formed from adduct 13, supporting the proposed 
mechanism outlined in Scheme 3.
Indolocarbazole 8 was advanced to K252a by coupling with furanose 9 (synthesized in four 
steps from methyl diazoacetoacetate) using conditions inspired by McCombie.[14] The 
desired isomer of the two glycosylated indolocarbazoles was then deprotected using TFA 
and thioanisole to provide the target with a longest linear sequence of seven steps.
2.2. Synthesis of the Welwitindolinone Carbon Skeleton
Stoltz, Wood, and co-workers continued to pursue their interest in donor–acceptor 
cyclopropane intermediates in their efforts toward the carbon skeleton of the 
welwitindolinone alkaloids.[15] Isolated in the 1990s from various cyanobacteria, some 
welwitindolinone alkaloids act as P-glycoprotein P-170 inhibitors with multidrug-resistance 
reversing activity.[16] Stoltz and Wood planned to form the carbon skeleton of the most 
potent member of the family, N-methylwelwitindolinone C isothiocyanate (16, Scheme 4) by 
elaboration of oxindole 17, itself formed by ring opening and further functionalization of a 
donor–acceptor cyclopropane derived from diazo compound 18. This cyclopropane was to 
be synthesized from isatin (20) via intermediate 19
In the forward direction, Wittig homologation of isatin (20) and cyclopropanation of the 
resulting olefin using a phosphorus ylide, followed by N-methylation produced stable 
cyclopropane 21, containing one aryl donor group and two vicinal carbonyl-type acceptor 
groups (Scheme 5). The ethyl ester was converted to α-diazo ketone 19, which upon 
treatment with rhodium(II) trifluoroacetate and Montmorillonite K-10 clay underwent an 
aryl C–H insertion step to afford tetracycle 22 in good yield.
Benzylic oxidation, tosylhydrazone formation, and elimination selectively formed the 
desired α-diazo ketone (18). Exposure of the corresponding rhodium carbenoid to allyl 
alcohol furnished cycloheptenone 24 in nearly quantitative yield. This reaction proceeds by 
initial insertion of the rhodium carbenoid into the O–H bond of allyl alcohol to form the 
transient cyclopropane 23, which features a strong enol donor substituent at one position and 
a carbonyl acceptor group at a vicinal position.This unstable intermediate undergoes 
fragmentation to produce cycloheptenone 24. Addition of ethynylmagnesium bromide and 
Claisen rearrangement gave enyne 25, which was advanced to the welwitindolinone carbon 
skeleton (17) by Lindlar hydrogenation and ring closing metathesis.
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2.3 Approach toward the Synthesis of Bielschowskysin
The Stoltz laboratory continued to investigate the strategy of cyclopropane fragmentation en 
route to larger carbocyclic rings in their approach toward the total synthesis of 
bielschowskysin (26, Scheme 6).[17] Isolated in 2004 from a Caribbean coral, 26 was found 
to possesses potent anticancer activity.[18] The simplified scaffold of 27 was chosen as a 
model system.
We planned to construct the highly functionalized core cyclobutane ring of 27 from donor–
acceptor cyclopropane 29 by a ring opening-Michael addition cascade sequence proceeding 
through intermediate 28. Cyclopropane 29 would be synthesized from diazoacetoacetate 30, 
which in turn would be accessed from simple aryl bromide (31)[19] and enone (32)[20] 
building blocks.
In the forward direction, alcohol 33 was synthesized from 31 using a three-step sequence 
consisting of borylation,[21] Suzuki cross-coupling with vinyl iodide 32,[22] and 
diastereoselective Luche reduction (Scheme 7). At this stage, optically pure material could 
be optained by the oxidative kinetic resolution protocol previously developed in our 
laboratory.[23] Advancement to diazoacetoacetate 30 was achieved through another three 
step sequence.[24] The key donor–acceptor cyclopropane 34 was obtained in moderate yield 
upon heating 30 with Cu(TBS)2 in toluene or DCE.
At this point, we envisioned that acetate cleavage and oxidation of the resulting alcohol 
would form cyclopropane 29, which would undergo the fragmentation-Michael addition 
cascade upon exposure to a Lewis acid. Unfortunately, acetate cleavage, oxidation, and 
treatment with lanthanum triflate in methanol produced cyclopentanol 38 (Scheme 8) rather 
than desired cyclobutane 27. This occurs as the result of an undesired translactonization 
following acetate hydrolysis to give 35. Oxidation and exposure to Lewis acid causes 
fragmentation of the cyclopropane to form a stabilized enolate and an extended 
oxocarbenium cation (36). Addition of one equivalent of methanol provides presumed 
intermediate 37, which proceeds through hemiketal formation and transesterification to 
afford the observed cyclopentanol (38). Unfortunately, all attempts to avoid this undesired 
translactonization were unsuccessful, and our synthetic efforts concluded at this point. This 
effort highlights the tenuous nature of such reactive, strained, and sterically constrained 
donor–acceptor cyclopropane systems.
2.4. Synthesis of the Core of the Gagunin Diterpenoids
We again chose to investigate a donor–acceptor cyclopropane fragmentation strategy in our 
construction of the carbocyclic core structure of the gagunin diterpenoids.[25] The gagunin 
family of natural products, isolated in 2002 from the sea sponge Phorbas sp., are 
characterized by a highly oxygenated 5–6–7 tricyclic core containing two all-carbon 
quaternary stereocenters. Depending on the extent of core oxygenation, these diterpenoids 
exhibit varying levels of cytotoxicity.[26]
We planned to target these natural products (exemplified by gagunin E, 39, Scheme 9) by 
late-stage cyclopentane formation and oxygenation of bicyclic diketone 40. This compound 
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would be reached from triflate 41, itself accessed from symmetrical precursor 42, a key 
intermediate in our previously reported total synthesis of the related cyathane diterpenoids.
[26]
In the forward direction, compound 42 was synthesized from diallyl succinate in two steps 
as a mixture of diastereomers.[27a] Subjection of this material to a double enantioselective 
decarboxylative allylic alkylation reaction[28] using conditions developed in our laboratory 
gave bis-allylated cyclohexane-1,4-dione 43 in good yield, good diastereoselectivity, and 
excellent enantioselectivity. Enol triflate formation afforded 41, which was converted to 
tetraene 44 in four steps. Ring-closing metathesis produced 40, containing the seven-
membered ring of the gagunin core. A four-step sequence consisting of enone carbonate 
protection and allyl functional group interconversions delivered α-diazo ketone 45.
Treatment of 45 with rhodium(II) acetate in dichloromethane gave cyclopropane 46 in good 
yield, and ring fragmentation with potassium carbonate in methanol furnished 47, containing 
the 5–6–7 tricyclic core of the gagunin diterpenoids in 31% yield. This appears to be an 
uncommon example of the reactivity of a donor–acceptor cyclopropanes with a transiently 
formed enolate acting as the donor[29]. Interestingly, cyclopropane 50 was also isolated from 
the fragmentation step in 27% yield.This unexpected compound is presumed to arise from 
deprotonation of 47 and subsequent retro-norcaradiene rearrangement. Alternatively, 50 
could be formed from 46 by carbonate cleavage, γ-deprotonation, and rearrangement.
2.5 Synthesis of the ABCD Ring System of Scandine
Having gained an appreciation for the utility of donor–acceptor cyclopropanes in synthesis, 
we planned to use a cyclopropane-olefin cycloaddition to construct the central C ring of 
scandine (51, Scheme 11), the parent compound of the Melodinus alkaloids.[30,31] Although 
they possess no known biological activity, these compounds attracted our interest due to 
their structural complexity, specifically the highly congested cyclopentane (C) ring.
Our original retrosynthesis is shown in Scheme 11. Late-stage E ring formation by carbenoid 
C–H insertion simplifies the target to tetracycle 52, which could arise from cyclopentane 53 
by nitro reduction, lactam ring closure, allylation, and selective ring-closing metathesis.[32] 
This cyclopentane could be formed by a palladium-catalyzed formal (3 + 2) cycloaddition 
between donor–acceptor cyclopropane 55 and nitroolefin 54.[33]
Unfortunately, despite significant effort, the synthesis of divinyl cyclopropane 55 proved 
elusive.[34] A revised retrosynthesis was developed, beginning with a monovinyl 
cyclopropane in the (3 + 2) reaction, and relying on a late-stage C–H vinylation to install the 
second vinyl group. The use of stable vinylcyclopropane 56 (Scheme 12) relied upon the 
known reactivity of such compounds to unveil their donor–acceptor reactivity upon 
treatment with palladium(0) complexes.[33]
In the forward sense, exposure of known monovinyl cyclopropane 56[35] and commercially 
available dinitrostyrene 54 to a palladium(0) phosphine complex afforded nitrocyclopentane 
57 in good yield as a mixture of diastereomers (Scheme 12). Treatment of the mixture with 
zinc dust in acetic acid resulted in reduction of both nitro groups and subsequent 
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lactamization to afford quinolone 58 as a 2:1 mixture of diastereomers. The desired minor 
diastereomer (58b) was allylated under reductive amination conditions affording 59. Amine 
protection and ring-closing metathesis furnished tetracycle 60 in good yield. Although 60 
does not contain the vinyl group present in the natural product, we were able to build four 
out of the five rings in only six steps from commercial sources.
3. Development of Novel Reactions of Donor–Acceptor Cyclopropanes 
and Activated Aziridines
3.1. Synthesis of Fused Carbocycles by a Tandem Wolff–Cope Rearrangement
Natural products containing fused 5–7 and 6–7 ring systems are of considerable interest to 
the synthetic community due to their biological potential.[36] Inspired by complex seven-
membered-ring-containing natural products like guanacastepene A (61, Scheme 13),[37] we 
devised a novel approach to the fused cycloheptadienone scaffold 62, which could be viewed 
as a synthetic intermediate en route to these targets. This scaffold could conceivably arise 
through a ketene-Cope rearrangement of a divinyl cyclopropane such as 63. While 
compounds like 63 do not fit the typical structural motif of a donor–acceptor cyclopropane, 
they are quite reactive. For any asynchronous reactions of these compounds, it is possible to 
envision the transition state featuring vicinal positive and negative charge stabilization, as is 
the case for most reactions of traditional donor–acceptor cyclopropanes. If the ketene moiety 
of 63 were to be accessed from an α-diazo ketone (64), it might be possible to form the 
desired cycloheptadienones in one pot through a tandem Wolff–Cope rearrangement.[38]
Donor–acceptor cyclopropane 64a was synthesized from methyl acetoacetate and sorbyl 
alcohol, and was treated with a variety of conditions known to effect Wolff rearrangements. 
Extensive optimization revealed that the use of silver benzoate and triethylamine with 
sonication in THF at 45 °C resulted in nearly quantitative yield of the desired fused 
cycloheptadienone product 65a as a single diastereomer (Scheme 14).
The substrate scope of the reaction is shown in Scheme 14. A range of hydroxyl protecting 
groups were tolerated (64a–c). Compounds containing a 1,1-disubstituted olefin (64d) or a 
monosubstituted olefin (64e and 64g) were also competent substrates. Finally, a tricyclic 
product (65f) and a 6–7 ring system (65g) could be formed in excellent yields. Interestingly, 
photochemical conditions were necessary to achieve high yields with the substrates 
containing monosubstituted olefins (64e and 64g).
Treatment of substrate 64a with the photochemical conditions shown in Scheme 14 resulted 
in the isolation of the fused cyclopentenone product 65h in good yield after a prolonged 
reaction time. This product is proposed to arise from a Norrish type I fragmentation of 
cycloheptadienone 65a, followed by intramolecular radical recombination, resulting in a net 
1,3-acyl migration process.[39]
The substrate scope of the tandem Wolff–Cope–1,3-acyl shift process is also shown in 
Scheme 14. As with the simpler Wolff–Cope rearrangement, this reaction is successful on 
substrates incorporating a variety of hydroxyl protecting groups (64a–c) and olefin 
substitutions (64h). This reaction is able to synthesize α-quaternary cyclopentenone 65k in 
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excellent diastereoselectivity. Finally, access to both the 5–5 (65h–j, 65k) and 5–6 (65l) 
fused ring systems is possible in good yields and diastereoselectivities.
3.2. Lewis Acid Mediated (3 + 2) Cycloadditions of Donor–Acceptor Cyclopropanes with 
Heterocumulenes
Inspired by our use of a donor–acceptor cyclopropane cycloaddition toward the construction 
of the scandine ABCD ring system, we have recently studied Lewis acid mediated 
cycloadditions of donor–acceptor cyclopropanes with heterocumulenes for the synthesis of 
five-membered heterocycles.[40,41] Similar cycloadditions of cyclopropanes with alkoxy 
donor groups were previously known, although the products were formed in low yield.[42] 
Furthermore, control of product stereochemistry was only possible through 
diastereoselective reactions making use of stereocenters remote from the site of reactivity. 
Inspired by the work of Johnson,[4a] Kerr,[4b] and others,[43,33b] we hoped that the use of 
aryl donor groups would allow for an enantiospecific reaction, occurring with transfer of 
stereochemical information at the benzylic position. This would enable rapid access to 
enantioenriched heterocyclic building blocks.
An investigation of Lewis acid, solvent, and temperature revealed that high yields of 
thioimidates (67, X=S) could be obtained in the reaction of allyl isothiocyanate with various 
donor–acceptor cyclopropanes (66) if stoichiometric tin(II) triflate in dichloromethane at 
23 °C was used. The scope of the reaction is shown in Scheme 15. Cyclopropanes 
containing electron-rich donor groups were found to be the most reactive (furnishing 
products 67b, 67e, and 67g). Cyclohexyl isothiocyanate was also found to be a competent 
dipolarophile (67l). Surprisingly, the isomeric thiolactams were never observed, providing 
complementarity to previously known reactions of alkoxy-substituted cyclopropanes with 
isothiocyanates.[42c,d].
Replacing the isothiocyanate with a carbodiimide allowed facile access to amidine products 
(67m–s). Examination of the scope of this reaction (Scheme 15) revealed that the 
carbodiimides were more reactive than the isothiocyanates, resulting in product formation 
even when combined with cyclopropanes unreactive with isothiocyanates (67r). Dialkyl- 
(67m–p), diaryl- (67s), and disilyl-carbodiimides[44] (67q, 67r) were all well tolerated.
Isocyanates were relatively unreactive in the tin-mediated conditions, but a screen of 
alternative Lewis acids showed iron(III) chloride as capable of recovering reactivity. In 
contrast to the reactions with isothiocyanates, only lactam products (68a–d) and not imidates 
were formed. The scope of the reaction is shown in Scheme 15.
A study of the cycloadditions on an enantioenriched cyclopropane showed that while the 
iron-mediated conditions resulted in racemic product, the tin-mediated reactions produced 
the desired heterocycles in high ee, with those substrates reacting fastest giving the product 
with greatest enantiopurity (Scheme 16). X-ray crystallographic analysis revealed that the 
reaction of (S)-66a with diisopropylcarbodiimide proceeds with inversion of configuration at 
the benzylic position. These observations on the reaction stereochemistry, along with the 
noted increased reactivity of electron-rich dipolarophiles and cyclopropanes with more 
electron-rich donor groups, have led to a proposed mechanism for the reactions of donor–
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acceptor cyclopropanes with isothiocyanates and carbodiimides (Scheme 16). Analogous to 
the mechanism proposed by Johnson and co-workers for the cycloadditions of donor–
acceptor cyclopropanes with aldehydes,[45,46] we postulate activation of the substrate with 
the Lewis acid forms a highly reactive intermediate with a weakened C–C bond that retains 
the configurational information of the starting material (69). An SN2-like attack of the 
dipolarophile at the benzylic stereocenter occurs with inversion of configuration, and the 
product of this step (70) undergoes ring closure to provide the observed heterocycles (67).
3.3. Stereoselective Lewis Acid Mediated (3 + 2) Cycloadditions of Activated Aziridines 
with Heterocumulenes
In addition to our work on cycloadditions of donor–acceptor cyclopropanes with 
heterocumulenes, we sought access to more highly nitrogenated heterocycles by replacing 
the cyclopropanes with related activated aziridines.[47] While these types of reactions were 
known at the outset of this work, there existed few examples using easily derivatizable N-
sulfonylaziridines,[48] and only a single example of a stereoselective reaction.[49]
An initial examination of several Lewis acids showed that while tin(II) triflate was not able 
to promote the reaction between N-tosyl-2-phenylazridine (71a) and allyl isothiocyanate, the 
use of zinc(II) halides resulted in the clean formation of desired iminothiazolidine 72a 
(Scheme 17). Zinc(II) bromide was chosen over the other zinc(II) halides due to its slightly 
superior yields and shorter reaction times.
The substrate scope of the reaction is shown in Scheme 17. A variety of aryl rings at the 
azridine 2-position (corresponding to the aryl donor group of the analogous donor–acceptor 
cyclopropanes) were tolerated, including those possessing electron-donating (71b, 71c) and 
electron-withdrawing (71d, 71e, 71g, 71h) groups. Primary and secondary alkyl 
isothiocyanates were successful dipolarophiles, producing iminothiazolidines 72k and 72l in 
excellent yields. Aryl isothiocyanates of varying electronics were also found to smoothly 
deliver the desired products (72m–o). The influence of the activating group on the aziridine 
nitrogen (corresponding to the acceptor group on the analogous donor–acceptor 
cyclopropane) was also explored, with a variety of sulfonyl substituents being well tolerated 
(affording 72p–r). Interestingly, while the unprotected aziridine was converted to the 
product (72s) in good yield, N-alkyl-or N-acylaziridines were unreactive (72t–v). 
Carbodiimides also proved to be compatible with the reaction conditions, providing access 
to iminoimidazolidines. Disilylcarbodiimide[50] (73a), diphenylcarbodiimide (73b–d), and a 
dialkylcarbodiimide (not shown) all reacted to form the products in moderate to excellent 
yields.
During the examination of the scope of aziridine-isothiocyanate reactions, we observed that 
a trans-2,3-disubstituted aziridine reacted with allyl isothiocyanate to form the cis-4,5-
disubstutited iminothiazolidine with exclusive diastereoselectivity (not shown). The 
apparently complete inversion of configuration at the benzylic position suggested the 
feasibility of a stereospecific variant of this reaction.
Exposure of enantioenriched N-tosyl-2-phenylazridine (R)-71a to allyl isothiocyanate and 
zinc(II) bromide resulted in isolation of the product iminothiazolidine (S)-72a in 42% ee. 
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Switching to zinc(II) chloride provided a small increase in product ee, and increasing the 
amount of isothiocyanate to 10.0 equivalents increased the ee of the product to 94% 
(Scheme 18, entry 1).
In addition to allyl isothiocyanate, the stereoselective reaction was tolerant of primary (entry 
2) and secondary (entry 3) alkyl isothiocyanates, although use of a tertiary isothiocyanate 
formed the product (entry 4) in diminished yield and enantiopurity. Aryl isothiocyanates of 
varying electronics were also tolerated, providing products in excellent yields with moderate 
to good retention of enantiopurity (entries 5–7). Changing the sulfonyl group on the 
aziridine nitrogen had minimal effect on the product enantiopurity (entries 8–10), but the 
unprotected aziridine suffered from poor reactivity and gave the product in low ee (entry 11).
Our mechanistic proposal is analogous to that invoked in our previous work with donor–
acceptor cyclopropanes. Coordination of the substrate with the Lewis acid forms a highly 
reactive intermediate with a weakened C–N bond that retains the configurational information 
of the starting material. The product is then formed by an SN2-like attack of the 
dipolarophile at the benzylic stereocenter and subsequent ring closure. This proposal is 
supported by the greater reactivity of aziridines with electron-rich aryl groups and more 
strongly electron-withdrawing sulfonyl groups on the nitrogen. Inversion of configuration at 
the benzylic position is also consistent with this mechanism.
4. Development of a Benzyne Acyl-Alkylation Reaction Proceeding 
through Presumed Donor–Acceptor Cyclobutane Intermediates
During efforts directed toward the arylation of enolates with benzyne to form all-carbon 
quaternary stereocenters, we found that treatment of β-ketoester 75 with benzyne (77, 
generated in situ from 74 and fluoride) unexpectedly resulted in the formation of 
disubstituted arene 76 in moderate yield.[51] This represented the first mild and direct 
example of the insertion of benzyne into a β-ketoester carbon–carbon bond,[52] and is likely 
produced by fragmentation of transiently generated donor–acceptor cyclobutane 79 (Scheme 
19).
This reactivity of benzyne with β-ketoesters proved to be quite general, and the scope of 
acyl-alkylation products produced is shown in Scheme 20. A variety of β-ketoesters were 
tolerated, including those containing branching or heteroatom-containing groups at the γ-
position (providing products 82a–f). β-Ketoesters derived from bulky and complex alcohols 
also afforded the acyl-alkylation products in good yield (82g and 82h). Substituted arynes 
could also be used, furnishing 82i–k in good to excellent yields. Finally, cyclic β-ketoesters 
were also capable substrates, reacting to give ring expansion products 82l–p, in moderate 
yields, representing a novel route to medium-sized rings. We have demonstrated the utility 
of this aryne insertion reaction in several total syntheses.[53] Furthermore, our mechanistic 
hypothesis has been invoked by numerous groups in recent disclosures of aryne insertion 
reactions.[54]
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5. Summary
Donor–acceptor cyclopropanes and related compounds like donor–acceptor cyclobutanes 
and activated aziridines have been used for decades to rapidly transform simple starting 
materials to complex products. Recent developments in the use of aryl donor groups have 
led to a resurgence of interest in these useful building blocks.
This perspective review has described our laboratory’s use of donor–acceptor cyclopropanes 
and related compounds in both natural products synthesis and methodological developments 
over the past 15 years with inspiration dating into the early 1990s. Specifically, we have 
described the origin of our interest in the area with Stoltz and Wood’s use of cyclopropane 
fragmentation strategies in the syntheses of K252a and the welwitindolinone C 
isothiocyanate core, as well as our continued use of these reactions in our efforts toward the 
synthesis of bielschowskysin and the gagunin terpenoids. We have also presented the 
application of a donor–acceptor cyclopropane-olefin cycloaddition reaction in the synthesis 
of the ABCD ring system of the Melodinus alkaloids. Additional efforts in the application of 
donor–acceptor cyclopropanes to natural products synthesis are currently underway in our 
laboratory.
As is the case in many laboratories, our endeavours in total synthesis often inspire the 
development of new methods.[55] In this case, our use of a donor–acceptor cyclopropane (3 
+ 2) cycloaddition toward scandine and other Melodinus alkaloids initiated further 
investigations into related reactivity, culminating in our reports of the cycloadditions of 
donor–acceptor cyclopropanes and activated aziridines with heterocumulenes. Additionally, 
in the course of unrelated synthetic studies, we discovered an aryne C–C insertion process 
presumably proceeding through a transient donor–acceptor cyclobutane intermediate. We 
look forward to the continued exploration of novel strained ring reactivity uncovered in our 
efforts in natural products synthesis.
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Scheme 1. 
Reactivity modes of donor–acceptor cyclopropanes.
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Scheme 2. 
Retrosynthetic analysis of K252a.
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Scheme 3. 
Total synthesis of K252a.
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Scheme 4. 
Retrosynthetic analysis of N-methylwelwitindolinone C isothiocyanate.
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Scheme 5. 
Synthesis of the carbon skeleton of Nmethylwelwitindolinone C isothiocyanate
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Scheme 6. 
Retrosynthetic analysis of bielschowskysin.
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Scheme 7. 
Synthesis of donor–acceptor cyclopropane 34. Cu(TBS)2 = bis(N-tert-
butylsalicylaldiminato)copper(II).
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Scheme 8. 
Cyclopropane fragmentation.
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Scheme 9. 
Retrosynthetic analysis of gagunin E.
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Scheme 10. 
Synthesis of the gagunin core.
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Scheme 11. 
Retrosynthetic analysis of scandine.
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Scheme 12. 
Synthesis of the ABCD ring system of scandine.
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Scheme 13. 
Synthetic inspiration for the tandem Wolff–Cope rearrangement.
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Scheme 14. 
Selected scope of the tandem Wolff–Cope rearrangement.
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Scheme 15. 
Selected scope of cycloadditions of donor–acceptor cyclopropanes with heterocumulenes.
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Scheme 16. 
Proposed mechanism of cyclopropane-heterocumulene cycloadditions.
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Scheme 17. 
Selected scope of cycloadditions of activated aziridines with heterocumulenes.
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Scheme 18. 
Scope of the stereoselective cycloaddition of activated aziridines with heterocumulenes.
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Scheme 19. 
Unexpected aryne C–C insertion and mechanistic proposal.
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Scheme 20. 
Scope of the acyl-alkylation of arynes.
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